CORRECTION: MULTIPLE SCLEROSIS DRUG (TYSABRI) MAY HAVE BEEN RESPONSIBLE FOR FOURTH CASE OF RARE BRAIN DISEASE

Yesterday, we reported that the FDA had been informed by Biogen Idec Inc. that a fourth person may have died from a rare and often fatal brain disease known as progressive multifocal leukoencephalopathy (PML) after short-term treatment with its embattled multiple sclerosis drug Tysabri. Actually, that person remains alive and is currently being treated for the disease.

This entry was posted in Legal News. Bookmark the permalink.


© 2005-2016 Parker Waichman LLP ®. All Rights Reserved.